BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

820 related articles for article (PubMed ID: 17148746)

  • 1. Targeting components of the stress system as potential therapies for the metabolic syndrome: the peroxisome-proliferator-activated receptors.
    Yumuk VD
    Ann N Y Acad Sci; 2006 Nov; 1083():306-18. PubMed ID: 17148746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of peroxisome proliferator-activated receptor agonists.
    Chang F; Jaber LA; Berlie HD; O'Connell MB
    Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome.
    Guan Y
    J Am Soc Nephrol; 2004 Nov; 15(11):2801-15. PubMed ID: 15504933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory role of peroxisome proliferator-activated receptor delta (PPAR delta) in muscle metabolism. A new target for metabolic syndrome treatment?
    Grimaldi PA
    Biochimie; 2005 Jan; 87(1):5-8. PubMed ID: 15733729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control].
    Bocher V; Chinetti G; Fruchart JC; Staels B
    J Soc Biol; 2002; 196(1):47-52. PubMed ID: 12134632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peroxisome proliferator-activated receptors and their relevance to dermatology.
    Friedmann PS; Cooper HL; Healy E
    Acta Derm Venereol; 2005; 85(3):194-202. PubMed ID: 16040401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
    Huang TH; Roufogalis BD
    Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.
    Libby P; Plutzky J
    Am J Cardiol; 2007 Feb; 99(4A):27B-40B. PubMed ID: 17307056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
    Brown JD; Plutzky J
    Circulation; 2007 Jan; 115(4):518-33. PubMed ID: 17261671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.
    Marx N; Duez H; Fruchart JC; Staels B
    Circ Res; 2004 May; 94(9):1168-78. PubMed ID: 15142970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Peroxisome proliferator-activated receptors (PPAR) in pathophysiology of the circulatory system and prospective use of agonists of these receptors in therapy].
    Bełtowski J; Wójcicka G; Jamroz A
    Postepy Hig Med Dosw; 2003; 57(2):199-217. PubMed ID: 12866356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peroxisome proliferator-activated receptors (PPARs) in the control of bone metabolism.
    Giaginis C; Tsantili-Kakoulidou A; Theocharis S
    Fundam Clin Pharmacol; 2007 Jun; 21(3):231-44. PubMed ID: 17521292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
    Gervois P; Fruchart JC; Staels B
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):145-56. PubMed ID: 17237841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of PPAR gamma agonists on cardiovascular function in obese, non-diabetic patients.
    Panunti B; Fonseca V
    Vascul Pharmacol; 2006 Jul; 45(1):29-35. PubMed ID: 16777491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
    Mansour M
    Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary modulators of peroxisome proliferator-activated receptors: implications for the prevention and treatment of metabolic syndrome.
    Guri AJ; Hontecillas R; Bassaganya-Riera J
    J Nutrigenet Nutrigenomics; 2008; 1(3):126-35. PubMed ID: 19776622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The human semaphorin 6B gene is down regulated by PPARs.
    Collet P; Domenjoud L; Devignes MD; Murad H; Schohn H; Dauça M
    Genomics; 2004 Jun; 83(6):1141-50. PubMed ID: 15177567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual acting and pan-PPAR activators as potential anti-diabetic therapies.
    Heald M; Cawthorne MA
    Handb Exp Pharmacol; 2011; (203):35-51. PubMed ID: 21484566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes.
    Blaschke F; Takata Y; Caglayan E; Law RE; Hsueh WA
    Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):28-40. PubMed ID: 16239592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?
    Ahmed W; Ziouzenkova O; Brown J; Devchand P; Francis S; Kadakia M; Kanda T; Orasanu G; Sharlach M; Zandbergen F; Plutzky J
    J Intern Med; 2007 Aug; 262(2):184-98. PubMed ID: 17645586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.